Alterity Therapeutics (ATHE) Operating Expenses (2014 - 2025)

Alterity Therapeutics' Operating Expenses history runs 11 years deep, the most recent figure standing at -$12.7 million for Q4 2025.

• On a quarterly basis, Operating Expenses fell 47.18% year-over-year to -$12.7 million in Q4 2025; TTM through Dec 2025 was -$21.3 million, a 9.34% decrease from a year earlier, with the FY2025 full-year figure at $12.7 million, down 100.0% from the prior year.
• Operating Expenses eased to -$12.7 million in Q4 2025 per ATHE's latest filing, from -$8.6 million in the prior quarter.
• Across five years, Operating Expenses topped out at -$8.6 million in Q4 2024 and bottomed at -$12.7 million in Q4 2025.
• The 5-year median for Operating Expenses is -$11.3 million (2022), against an average of -$11.0 million.
• Across the five-year window, Operating Expenses advanced 20.68% in 2024 and sank 47.18% in 2025, its largest moves.
• Year by year, Operating Expenses stood at -$11.5 million in 2021, then grew by 2.0% to -$11.3 million in 2022, then gained by 3.77% to -$10.8 million in 2023, then grew by 20.68% to -$8.6 million in 2024, then plunged by 47.18% to -$12.7 million in 2025.
• Per Business Quant, the three latest ATHE Operating Expenses figures stand at -$12.7 million (Q4 2025), -$8.6 million (Q4 2024), and -$10.8 million (Q4 2023).